| __timestamp | BioMarin Pharmaceutical Inc. | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 2395000 |
| Thursday, January 1, 2015 | 152008000 | 9057000 |
| Friday, January 1, 2016 | 209620000 | 393000 |
| Sunday, January 1, 2017 | 241786000 | 79309000 |
| Monday, January 1, 2018 | 315264000 | 134428000 |
| Tuesday, January 1, 2019 | 359466000 | 175431000 |
| Wednesday, January 1, 2020 | 524272000 | 124165000 |
| Friday, January 1, 2021 | 470515000 | 121875000 |
| Saturday, January 1, 2022 | 483669000 | 10114000 |
| Sunday, January 1, 2023 | 577065000 | 9206000 |
| Monday, January 1, 2024 | 580235000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial for investors and stakeholders. Over the past decade, BioMarin Pharmaceutical Inc. and Wave Life Sciences Ltd. have showcased contrasting trajectories in their cost of revenue. BioMarin, a leader in the field, has seen its costs rise steadily, peaking in 2023 with a 345% increase from 2014. This growth reflects its expanding operations and market reach. In contrast, Wave Life Sciences, a smaller player, experienced a more volatile pattern, with costs spiking in 2019 before stabilizing. By 2023, Wave's costs were approximately 7% of BioMarin's, highlighting the scale difference between the two companies. This comparison not only underscores the diverse strategies within the biotech sector but also offers insights into how companies manage growth and operational expenses over time.
Comparing Cost of Revenue Efficiency: Sanofi vs Wave Life Sciences Ltd.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: BeiGene, Ltd. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Wave Life Sciences Ltd.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.
BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Galapagos NV
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Wave Life Sciences Ltd.'s Expenses
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Wave Life Sciences Ltd.
Ligand Pharmaceuticals Incorporated vs Wave Life Sciences Ltd.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Wave Life Sciences Ltd. and Galapagos NV
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Evotec SE